Forendo Pharma Closes 12 Million Euros to Develop Novel Targeted Therapy

27/10/2014 - 2 minutes

Forendo Pharma successfully closed €12M for further development of treatment against endometriosis. Novartis Venture Fund and MS Ventures will participate in the financing round, alongside the current major shareholders Karolinska Development, Novo A/S and Finnvera.

Endometriosis is a chronic disease affecting up to 10% of the women between adolescence and menopause. There is a large unmet medical need as the current available therapies are unspecific, focusing on pain medication, hormonal treatments, and surgery, leaving many patients without satisfactory relief of their chronic pelvic pain either because of poor efficacy or poor tolerability. The total annual societal cost of endometriosis in Europe and the USA is estimated to be beyond €100Bn.

The money will be used to finance the further development of Forendo’s clinical candidate FP-5677 up until clinical proof-of-concept for the treatment of endometriosis. FP-5677 inhibits the enzyme 17-beta-hydroxysteroid dehydrogenase 1 and is a novel drug with potential to become the first specific treatment for endometriosis through its organ specific regulation of estrogen hormone activity. Forendo will also progress early phase programs for other hormone dependent diseases. 

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!